Chaired by Martin Reck with Johan Vansteenkiste and Keith Kerr
Held on Thursday 14th April 2016, Geneva, Switzerland
The faculty provided insight and guidance on the latest developments when treating NSCLC and how we can use our biological knowledge to improve both treatment pathways and outcomes in NSCLC. The scientific summary includes a presentation from Keith Kerr on trail markers in squamous NSCLC, a case study, presented by Johan Vansteenkiste and a panel discussion on patient management in the targeted age, Martin Reck.
Scientific summary
The report covers:
- a presentation from Keith Kerr on trail markers in squamous NSCLC: signposts for clinical efficiency
- a case study, presented by Johan Vansteenkiste: navigating the advanced NSCLC patient pathway
- a panel discussion on patient management in the targeted age: finding the way through increased complexity – chaired by Martin Reck
Learning objectives
Following attendance at this symposium delegates are expected to:
- Understand how best to use biomarkers to guide therapy for advanced squamous NSCLC
- Understand and demonstrate knowledge on the latest treatment pathways for patients with advanced squamous NSCLC
- Understand the emerging therapies for advanced squamous NSCLC and the new treatment paradigms they raise
Faculty bios
Educational grant
This independent programme is made possible thanks to educational sponsorship from Eli Lilly and Company.
Produced by Springer Healthcare IME.
Accreditation
Contact us
Email: IME@springer.com
Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK